SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.

Autor: Braun J; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany., Loyal L; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany., Frentsch M; Department of Hematology, Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Wendisch D; Berlin Institute of Health (BIH), Berlin, Germany., Georg P; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany., Kurth F; Berlin Institute of Health (BIH), Berlin, Germany.; Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Hippenstiel S; Berlin Institute of Health (BIH), Berlin, Germany., Dingeldey M; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany., Kruse B; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany., Fauchere F; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany., Baysal E; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany., Mangold M; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany., Henze L; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany., Lauster R; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany.; I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Mall MA; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.; Department of Pediatric Pulmonology, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany., Beyer K; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany., Röhmel J; Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany., Voigt S; Department of Infectious Diseases, Robert Koch Institut, Berlin, Germany., Schmitz J; Miltenyi Biotec, Bergisch Gladbach, Germany., Miltenyi S; Miltenyi Biotec, Bergisch Gladbach, Germany., Demuth I; Interdisciplinary Metabolism Center, Biology of Aging (BoA) group, Charité-Universitätsmedizin Berlin, Berlin, Germany., Müller MA; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Hocke A; Berlin Institute of Health (BIH), Berlin, Germany., Witzenrath M; Berlin Institute of Health (BIH), Berlin, Germany., Suttorp N; Berlin Institute of Health (BIH), Berlin, Germany., Kern F; Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK.; JPT Peptide Technologies, Berlin, Germany., Reimer U; JPT Peptide Technologies, Berlin, Germany., Wenschuh H; JPT Peptide Technologies, Berlin, Germany., Drosten C; Department of Pediatric Pulmonology, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Corman VM; Institute of Virology, Charité-Universitätsmedizin Berlin, Berlin, Germany., Giesecke-Thiel C; Max Planck Institute for Molecular Genetics, Berlin, Germany. giesecke@molgen.mpg.de., Sander LE; Berlin Institute of Health (BIH), Berlin, Germany. leif-erik.sander@charite.de., Thiel A; Si-M/'Der Simulierte Mensch', Technische Universität Berlin and Charité-Universitätsmedizin Berlin, Berlin, Germany. andreas.thiel@charite.de.; Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany. andreas.thiel@charite.de.
Jazyk: angličtina
Zdroj: Nature [Nature] 2020 Nov; Vol. 587 (7833), pp. 270-274. Date of Electronic Publication: 2020 Jul 29.
DOI: 10.1038/s41586-020-2598-9
Abstrakt: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2 . Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4 + T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4 + T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4 + T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
Databáze: MEDLINE
Externí odkaz: